| 5/9/2021 |
Reviewing Integer (NYSE:ITGR) and Axion Power International (OTCMKTS:AXPWQ) |
baseballnewssource.com |
... in the United States, Puerto Rico, Costa Rica, and internationally. It operates in two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology , electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure ... |
| 5/9/2021 |
Doubling Down on Immunotherapy in Advanced Melanoma |
medpagetoday.com |
... 1/L1 treatment did not influence likelihood of response to pembrolizumab and ipilimumab, reported Jason J. Luke, MD, of the UPMC Hillman Cancer Center in Pittsburgh, and co-authors in the Journal of Clinical Oncology ."The combination of pembrolizumab plus low-dose ipilimumab demonstrated significant antitumor activity and tolerability in a multicenter clinical trial," they concluded. "This study demonstrated long-term responses, suggesting that durable survival -- a hallmark of immunotherapy ... |
| 5/8/2021 |
Switch of breast tumors to HER2-low in recurrence may provide greater therapeutic options |
bioengineer.org |
meetings/esmo-breast-2021-virtual2 Abstract 4MO_PR ‘HER2-low breast cancer: evolution from primary breast cancer to relapse.’ will be presented by Federica Miglietta during the Mini Oral Session 2 on Saturday, 8 May, 12:45-14:00 (CEST). Annals of Oncology , Volume 32, Supplement 2, May 2021About the European Society for Medical Oncology (ESMO) ESMO is the leading professional organisation for medical oncology . With more than 25,000 members ... |
| 5/8/2021 |
Daiichi Sankyo, AstraZeneca's $5B Enhertu follow-up shows early signs of success in breast cancer |
FierceBiotech |
... which is further along, Daiichi and AstraZeneca published the first look at Dato-DXd in triple-negative breast cancer (TNBC) at a late-breaking mini oral presentation at the 2021 European Society of Medical Oncology (ESMO) Breast Cancer Virtual Congress conference Saturday.Nearly one year ago, AZ agreed to pay $1 billion upfront over two years for ex-Japan rights to the drug, which works as an ADC that targets ... |
| 5/8/2021 |
Datopotamab Deruxtecan Late-Breaking Data at ESMO Breast Shows Promising Preliminary Response and Disease Control in Patients with Metastatic Triple Negative Breast Cancer | Business Wire |
Business Wire |
... standard treatment.These preliminary data from the TNBC cohort of the TROPION-PanTumor01 phase 1 study were presented as a late-breaking mini oral presentation (Abstract LBA4) at the 2021 European Society of Medical Oncology (ESMO) Breast Cancer Virtual Congress ( ESMOBreast21).TNBC accounts for approximately 10 to 15% of breast cancer cases and is associated with higher disease recurrence and worse prognosis compared to other breast cancer subtypes. 1,2,3 It ... |
| 5/8/2021 |
North America Kristen Rat Sarcoma Kras |
databridgemarketresearch.com |
... and Canada. Market leader is Thermo Fisher Scientific Inc. 15% to 20%. The company has gained outstanding sale through providing Kristen rat sarcoma (KRAS) detection devices.In January 2021, Illumina, Inc. had announced the oncology partnerships with Bristol Myers Squibb, Kura Oncology , Myriad Genetics and Merck for Advanced Comprehensive Genomic Profiling. The partnerships would result in the company’s aim to develop standardized tools for precision oncology . It would deliver ... |
| 5/8/2021 |
Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd and Merck KGaA Dominating North America Kirsten Rat Sarcoma (KRAS) Market in 2020 |
databridgemarketresearch.com |
... rat sarcoma (KRAS) market is a highly consolidated market which includes specific Kirsten rat sarcoma (KRAS) product portfolio. This has helped the For instance, in October 2018, Illumina, Inc. had launched the True Sight Oncology 500. The liquid biopsy panel is a comprehensive pan-cancer assay which has been designed to identify and detect known and upcoming tumor biomarkers. The panel launched by the company were used for molecular testing ... |
| 5/8/2021 |
Thermo Fischer Scientific Inc, Illumina, Inc. and Abbott Dominating Asia-Pacific Kirsten Rat Sarcoma (KRAS) Market in 2020 |
databridgemarketresearch.com |
... number of key players as well as local The major players dealing in Kirsten Rat Sarcoma (KRAS) product portfolio. This helped companiesFor instance,In October 2018, Ilumina Inc had launched the True Sight Oncology 500. The liquid biopsy panel, is a comprehensive pan-cancer assay, which has been designed to identify and detect known and upcoming tumor biomarkers. The panel launched by the company were used for molecular testing ... |
| 5/8/2021 |
Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, and Biocartis Dominating Europe Kirsten Rat Sarcoma (KRAS) Market in 2020 |
databridgemarketresearch.com |
... Europe Kirsten Rat Sarcoma (KRAS) Market is a highly consolidated market, which includes specific Kirsten Rat Sarcoma (KRAS) product portfolio. This helpedFor instance,In October 2018, Ilumina Inc had launched the True Sight Oncology 500. The liquid biopsy panel, is a comprehensive pan-cancer assay, which has been designed to identify and detect known and upcoming tumor biomarkers. The panel launched by the company were used for molecular testing ... |
| 5/8/2021 |
Nwaneri: Nigerian Oncologist On Global Stage By Onyedika Agbedo |
jimidisu.com |
... of life has today earned him a place in the league of leading oncologists in the world, to the pride of many Nigerians.In November last year, he assumed the presidency of the Iowa Oncology Society, an organisation of medical oncologists and allied health professionals with focus on cancer care in the State of Iowa, United States (U.S.). The position places the 1989 graduate of the University of Nigeria, Enugu ... |
| 5/8/2021 |
Chemotherapy Nausea Linked to Stress, Neuropsych Symptoms |
letlifehappen.com |
High frequency of CIN leads to stress and more severe neuropsychological symptomsPatients who suffer frequent chemotherapy-induced nausea (CIN) are more likely to experience neuropsychological symptoms and stress characteristics, according to a study presented at the virtual Oncology Nursing Society annual meeting.Compared with patients who did not experience nausea during their chemotherapy, the 28% of patients with high nausea occurrence across assessments had significantly higher scores for depression ... |
| 5/8/2021 |
Bayer Aktiengesellschaft (FRA:BAYN) Share Price Crosses Above 200-Day Moving Average of $50.48 - American Banking News |
American Banking News |
... a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology , hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.Recommended Story: Straddles Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a ... |
| 5/8/2021 |
Bayer Aktiengesellschaft (FRA:BAYN) Stock Price Crosses Above 200 Day Moving Average of $50.48 |
slatersentinel.com |
... a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology , hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy ... |
| 5/8/2021 |
Critical Comparison: Idera Pharmaceuticals (NASDAQ:IDRA) & Genetic Technologies (NASDAQ:GENE) |
dispatchtribunal.com |
... Idera Pharmaceuticals on 5 of the 9 factors compared between the two stocks.About Idera PharmaceuticalsIdera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors ... |
| 5/8/2021 |
UCHealth sending supplies to India, which has been ravaged by COVID-19 |
greeleytribune.com |
The more he saw and heard about the ongoing carnage COVID-19 was unleashing in India, the more upset Dr. Saketh Guntupalli became.“I said I can’t watch this anymore, we need to do something,” recalled Guntupalli, director of gynecologic oncology at UCHealth University of Colorado Hospital.Not one to sit on the sidelines, he reached out to Tom Gronow, COO at UCHealth, asking for permission to gather ... |
| 5/8/2021 |
Bayer Aktiengesellschaft (FRA:BAYN) Share Price Crosses Above 200-Day Moving Average of $50.48 |
Mayfield Recorder |
... a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology , hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.Recommended Story: Straddles Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a ... |
| 5/8/2021 |
Gilead Sciences (NASDAQ:GILD) Lifted to Hold at Zacks Investment Research - Ticker Report |
Ticker Report |
... remdesivir) for the treatment of COVID-19. The COVID-19 pandemic is expected to further impact HCV treatment initiations and HIV new starts and switches. Nevertheless, Gilead’s efforts to boost and diversify the oncology segment is positive. The CAR T cell therapy franchise, comprising Yescarta and Tecartus, is also gaining traction. Incremental sales of Veklury for the treatment of COVID-19 also boosted the top line and the trend ... |
| 5/8/2021 |
Gilead Sciences (NASDAQ:GILD) Rating Increased to Hold at Zacks Investment Research |
baseballnewssource.com |
... remdesivir) for the treatment of COVID-19. The COVID-19 pandemic is expected to further impact HCV treatment initiations and HIV new starts and switches. Nevertheless, Gilead’s efforts to boost and diversify the oncology segment is positive. The CAR T cell therapy franchise, comprising Yescarta and Tecartus, is also gaining traction. Incremental sales of Veklury for the treatment of COVID-19 also boosted the top line and the trend ... |
| 5/8/2021 |
Moon Explores Use of Avelumab Maintenance in Metastatic Bladder Cancer |
targetedonc.com |
2021 MJH Life Sciences ‚Ñ¢ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved. Moon Explores Use of Avelumab Maintenance in Metastatic Bladder Cancer May 8, 2021 Case-Based Roundtable Meetings Spotlight , Case-Based Roundtable Meetings Spotlight April 2, 2021, Pages: 81Helen Moon, MD, reviewed the data from the JAVELIN Bladder 100 trial, which support the use of avelumab as maintenance therapy for patients with metastatic bladder cancer ... |
| 5/8/2021 |
Rain Therapeutics, Canadian National Railway See Activist Action |
barrons.com |
... or intentions must be reported in amended filings. This material is from April 29 through May 5, 2021. Source: InsiderScore.comOriginal Filings Rain Therapeutics (RAIN)Boxer Capital initiated a position in the clinical-stage oncology biotech firm of 1,894,192 shares. Rain Therapeutics’ April 23 initial public offering priced shares at $17 each. Boxer Capital purchased 1,025,000 Rain Therapeutics shares through the offering, and bought 150,000 additional shares that same ... |